{
  "id": 6104915,
  "title": "Endothelin receptor blockade potentiates adoptive T cell and CAR T cell therapies",
  "url": "https://urgent.news/2026/09/06/endothelin-receptor-blockade-potentiates-adoptive-t-cell-and-car-t",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-06T00:00:00.000Z",
  "source": {
    "name": "bioRxiv",
    "slug": "biorxiv",
    "url": "https://www.biorxiv.org/content/10.64898/2026.09.02.748239v1?rss=1"
  },
  "original_language": "en",
  "account": "Adoptive T cell therapies have shown promise in treating certain types of blood cancers, but their effectiveness is often limited by biological factors that hinder long-lasting antitumor responses. To explore if targeting the endothelin receptor pathway, which influences vascular, stromal, and immune functions involved in antitumor responses, could boost the success of T cell-based cellular immunotherapies, researchers conducted experiments using mouse models of breast cancer and lymphoma. The study involved administering endothelin receptor blockade alongside adoptive T cell therapies (non-engineered T cells and anti-CD19 CAR T cells) in combination with or without immune checkpoint inhibitors. The findings revealed that blocking endothelin receptors significantly boosted response rates across both therapy types, with the combination of immune checkpoint inhibitors leading to the highest frequency of complete responses and the most enduring tumor control. Mice that maintained complete responses exhibited resistance to tumor reinjection, indicating robust long-term immune protection. By analyzing T cells within the tumors, researchers identified specific intratumoral T cell states linked to successful tumor control, with CD2 expression emerging as a consistent characteristic among these populations. The study concludes that endothelin receptor blockade could serve as a rational approach to augment the efficacy of T cell-based cellular immunotherapies, offering a compelling case for further clinical investigation into this strategy.",
  "summary": "Adoptive T cell therapies have transformed the treatment of selected haematological malignancies but remain limited in many cancer settings by biological barriers that restrict effective and durable antitumour responses. Here, we investigated whether pharmacological blockade of the endothelin receptor pathway, which regulates vascular, stromal and immune processes relevant to antitumour…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}